

Central nervous system stimulants, adolescent use of, 494

Central precocious puberty (CPP), 917, 917*b*

Central venous access device (CVAD), 610-611

- long-term, 610, 611*t*, 612*f*
- short-term, 610

Cephalhematoma, 229-230, 230*f*

Cephalopelvic disproportion, 229

Cereal, iron-fortified

- for infants, 319-320
- for toddler, 366-367

Cerebellar function, 109-110, 109*b*

Cerebral dysfunction, 872-910

- altered state of consciousness in, 873-874, 874*b*, 874*f*
- in aseptic meningitis, 893-894, 894*t*
- in bacterial meningitis, 890-893, 891*b*, 893*b*
- cerebral compromise and, 878-882
- diagnostic procedures of, 876-878, 877*t*-878*t*
- in encephalitis, 894-895, 894*b*
- general aspects of, 872
- in head injury, 882-888, 883*f*, 885*b*-887*b*
- in hydrocephalus, 880*b*, 906-908, 906*f*
- increased intracranial pressure in, 872, 873*b*, 873*f*
- intracranial infections in, 890-896
- malformations in, 906-908
- neurologic examination in, 874-876, 875*f*-876*f*
- neurologic status in, evaluation of, 872-878
- in rabies, 895
- in Reye syndrome, 895-896